drugset / Trial / NCT00388089
Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
24 enrolled
University of California, Davis
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with topotecan may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib and topotecan in treating patients with advanced solid tumors.
Timeline
- Start
- 2004-12
- Primary completion
- 2007-11
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | Intravenous |
| Subject | Topotecan | Small molecule | 3 mg/m2 | Intravenous |
| Subject | Topotecan | Small molecule | 4 mg/m2 | Intravenous |